Welcome to our dedicated page for MILESTONE SCIENTIFIC SEC filings (Ticker: MLSS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Milestone Scientific Inc. filings document material events for a NYSE American-listed operating company with common stock trading under MLSS. Recent disclosures cover private placements of common stock and warrants, registration-rights and purchase agreements, use-of-proceeds language, and amendments to corporate governing documents that affect authorized share capital.
The company’s SEC records also describe shareholder voting results, director elections, auditor ratification and auditor changes, material agreements involving stockholder transfer restrictions, and liquidity-related audit disclosure, including going-concern language in the independent auditor’s report.
Milestone Scientific Inc. (MLSS) filed Pre-Effective Amendment No. 1 to its shelf registration statement on Form S-3 (File No. 333-298804). The amendment’s sole purpose is to correct a clerical error where the company’s signature block was inadvertently omitted from the original filing.
The amendment also adds an updated Exhibit 5.1, an opinion of Tarter Krinsky & Drogin LLP that now bears a conformed signature and includes the related consent. Other than these technical changes to the cover page, exhibit index, signatures, and Exhibit 5.1, the prospectus and remaining disclosure remain unchanged.
Milestone Scientific Inc. (MLSS) has filed a shelf registration on Form S-3 to offer, from time to time, up to $45,000,000 of common stock, preferred stock, warrants, subscription rights and units. This includes $41,763,620 of previously registered but unsold securities carried forward under Rule 415(a)(6).
The company’s common stock trades on NYSE American under “MLSS,” with a September 2, 2026 closing price of $0.46 per share. As of September 8, 2026, it had 90,644,403 common shares outstanding out of 135,000,000 authorized, and 5,000,000 authorized preferred shares with none outstanding. Milestone qualifies as a smaller reporting company and highlights significant risks, including recurring losses, going concern uncertainty, capital needs, NYSE American listing compliance, manufacturing and supply risks, reimbursement and regulatory exposure, and international and China-related risks.
Net proceeds from any future takedowns are expected to be used for working capital and general corporate purposes, including R&D, general and administrative expenses, capital expenditures, potential IP or technology licensing or acquisitions, development of the next-generation dental instrument, and possible business acquisitions. Actual terms, pricing, specific uses and any underwriters or agents will be detailed in separate prospectus supplements for each offering.
Milestone Scientific Inc. reported higher sales but continued losses for the three and six months ended June 30, 2026. Net product sales were $2.84 million for the quarter and $5.00 million year-to-date, up from $2.32 million and $4.56 million in 2025, driven mainly by Dental segment growth and renewed sales into China, plus early-stage growth in Medical CompuFlo® epidural systems.
Gross profit rose to $1.91 million for the quarter and $3.47 million for six months, with gross margin of about 67.2%, slightly below the prior year due to mix and higher product costs, including tariffs. Operating expenses declined to $5.36 million for six months from $6.75 million, reflecting lower regulatory, consulting and R&D spend, partially offset by higher stock-based compensation, royalties and marketing.
The company recorded a six‑month net loss of $1.90 million, improved from a $3.48 million loss a year earlier, but has an accumulated deficit of $135.7 million. Cash and cash equivalents were $2.07 million and working capital about $3.7 million at June 30, 2026. A $1.81 million April 2026 private placement and related warrants strengthened liquidity, yet management states that recurring losses, negative operating cash flows and limited cash raise substantial doubt about the ability to continue as a going concern without additional revenue growth or financing.
Milestone Scientific Inc. reported outcomes of its 2026 annual stockholders meeting and related board actions. Stockholders elected five incumbent directors to serve until the 2027 annual meeting, approved increasing authorized common shares from 125,000,000 to 135,000,000, expanded the Amended and Restated 2020 Equity Incentive Plan from 11,500,000 to 28,750,000 shares, approved on an advisory basis compensation of named executive officers, and ratified Grassi & Co. Certified Public Accountants, PC as independent auditors. At the record date there were 88,449,412 common shares outstanding, and 44,335,594 shares, or 50.12%, were represented, constituting a quorum.
The board re-elected Kelly Ulto and Greg Shilling as directors effective July 27, 2026, to serve until the 2027 annual meeting, reaffirmed that both are independent, determined that Ulto qualifies as an audit committee financial expert, and appointed Ulto and Shilling as chairs and members of various board committees.
Milestone Scientific Inc. reports that three directors, Benedetta Casamento, Dr. Didier Demesmin and Neal Goldman, have delivered notices electing to convert the remaining principal and accrued interest on their Convertible Bridge Notes into common stock. These notes were originally issued as part of a series of promissory notes with aggregate principal of $800,000.
The outstanding principal subject to these elections is $116,495.47 for Ms. Casamento, $58,247.73 for Dr. Demesmin and $291,238.66 for Mr. Goldman. Conversions will occur automatically once the common stock’s Fair Value is at least $0.50 per share and each director is permitted to trade under the company’s Insider Trading Policy. No shares have been issued under these elections as of the report date.
Milestone Scientific Inc. restructured key governance and executive arrangements, including a new agreement with founder Leonard Osser, the appointment of two new independent directors, and elevating Benedetta Casamento from Chair of the Board to Executive Chairman.
The new Osser agreement cancels his prior consulting and succession arrangements, waives certain past compensation in exchange for specified catch-up payments and expense reimbursement, and reduces his role and pay to an advisory position at $48,000 per year plus health benefits and car allowance. Osser and his wife also agreed to lock-up most of their shares through April 20, 2027.
The Board appointed Kelly Ulto and Greg Shilling as independent directors and committee members, with Ulto designated as an audit committee financial expert. Casamento’s new Executive Chairman role adds a $75,000 annual salary, equity-based Director Equivalent compensation, and a one-time $100,000 restricted stock grant, alongside previously disclosed participation in $800,000 of Convertible Bridge Notes and a recent 7,962,963-unit private placement at $0.27 per unit.
Milestone Scientific is asking stockholders to approve several governance and capital structure changes at its virtual annual meeting on July 27, 2026. Stockholders will vote on electing five directors, an advisory say‑on‑pay resolution, and ratifying Grassi & Co. as auditor for 2026.
A key proposal would amend the certificate of incorporation to raise authorized common shares from 125,000,000 to 135,000,000, compared with 88,449,412 shares outstanding as of May 28, 2026. Another proposal would expand the 2020 Equity Incentive Plan from 11,500,000 to 28,750,000 shares and support a new performance‑based RSU sub‑plan that allocates up to 17,234,635 shares, including 11,202,513 PRSUs granted to three senior officers.
The proxy details 2025 executive pay, including total compensation of $795,019 for CEO Eric Hines and $723,796 for Senior VP Jason Papes, largely driven by option awards. It also shows a 2025 net loss of $5,722,216 and 2025 total shareholder return of 28.72 on a $100 base, alongside related‑party items such as $800,000 of 2025 convertible bridge notes purchased by directors.
Milestone Scientific Inc. is asking shareholders at its virtual Annual Meeting on to elect five directors and approve three governance proposals. Key votes seek to increase authorized common shares from 125,000,000 to 135,000,000, expand the 2020 Equity Incentive Plan from 11,500,000 to 28,750,000, and ratify auditors. The record date shows 88,449,412 shares outstanding as of May 28, 2026. The proxy also discloses a previously approved Exchange Program repricing certain options to a $0.31 exercise price and outstanding director and executive compensation details.
Milestone Scientific Inc. registers the resale of up to 15,925,926 shares of common stock (7,962,963 Initial Shares and 7,962,963 Warrant Shares) to satisfy a registration rights covenant. The shares were issued in a Private Placement closed on April 20, 2026 at $0.27 per Unit.
The Company will not receive proceeds from resales by the selling stockholders; however, upon cash exercise of Warrants the company would receive $0.3375 per share, representing up to $2,687,500 in gross proceeds if exercised in full. Context: 88,449,412 shares outstanding as of May 28, 2026, and a reported closing price of $0.37 on May 26, 2026. The prospectus discloses a going concern note in the audited financials and that the Company is not currently in compliance with NYSE American listing equity thresholds.